Date: 2017-02-10
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: UCB (Belgium)
Product: UCB7665
Action mechanism:
Disease: myasthenia gravis
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Country:
Trial
details: The study is a multicenter, randomized, investigator- and subject-blind, placebo-controlled, treatment sequence study evaluating the safety, tolerability, and efficacy of UCB7665 in subjects with moderate to severe myasthenia gravis. (NCT03052751)
Latest
news: * On February 10, 2017, a Phase 2 trial sponsored by UCB was published on the NIH website ClinicalTrials.gov for UCB7665.
